The HemOnc Pulse
Is MRD Negativity the New Benchmark in ALL Treatment Strategies?
Mar 14, 2024
Discussing the role of measurable residual disease in ALL treatment, advancements in TKIs for Ph+ ALL, medication-based treatments for high-risk patients, innovative strategies for Ph- leukemia patients, and the importance of achieving MRD negativity in leukemia therapy.
19:47
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Tyrosine kinase inhibitors have significantly improved survival outcomes in Ph+ ALL, reducing the need for transplantation.
- Integrating immunotherapy upfront in Philadelphia negative ALL has led to universal response rates and MRD negativity in 80% of cases, enhancing survival rates.
Deep dives
Treatment Advances for Philadelphia Positive Acute Lymphoblastic Leukemia
In the podcast, Dr. Elijah Bohr from MD Anderson Cancer Center discusses treatment strategies for Philadelphia positive acute lymphoblastic leukemia (ALL). Historically, patients with this type of ALL had poor outcomes, with survival rates of only 10%. The introduction of tyrosine kinase inhibitors improved outcomes significantly to 40-60%, addressing the issue of relapses due to resistance. The combination of chemotherapy and potent new drugs like ponatinib has led to survival rates of 75%, eliminating the need for transplantation in some cases.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
